Abstract
ACUTE myeloid leukemia (AML) in children and adolescents has traditionally been one of the hardest childhood cancers to successfully treat. Overall survival in the 1960s was well under 10%. With the use of intensive induction and post-remission chemotherapy, judicious use of bone marrow transplantation and improved supportive care, the outcome for children and adolescents has improved steadily and now 50-60% of affected patients diagnosed in developed countries are cured [1-5]. EPIDEMIOLOGY
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
